EyeGene Inc. (KOSDAQ:185490)
South Korea · Delayed Price · Currency is KRW 1,940.00
+14.00 (0.73%)
At close: Sep 3, 2026
EyeGene Revenue
EyeGene had revenue of 1.27B KRW in the quarter ending March 31, 2026, with 55.55% growth. This brings the company's revenue in the last twelve months to 4.02B, up 10.16% year-over-year. In the year 2025, EyeGene had annual revenue of 3.57B with 6.29% growth.
Revenue (ttm)
4.02B
Revenue Growth
+10.16%
P/S Ratio
19.19
Revenue / Employee
n/a
Employees
n/a
Market Cap
86.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57B | 211.02M | 6.29% |
| Dec 31, 2024 | 3.36B | 230.37M | 7.37% |
| Dec 31, 2023 | 3.13B | -2.17B | -40.96% |
| Dec 31, 2022 | 5.29B | 2.05B | 63.27% |
| Dec 31, 2021 | 3.24B | -121.31M | -3.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| Psomagen | 60.70B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.79B |
| BIO-FD&C | 19.53B |
| CORESTEMCHEMON | 18.29B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.57B |